Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders

BACKGROUND The use of monoclonal antibodies therapy (MAT) in early mild to moderate Coronavirus disease 2019 (COVID-19) has gained importance in recent times. However, there is limited information on the safety and efficacy of MAT in treating COVID-19 in patients with underlying rheumatologic diseas...

Full description

Saved in:

Bibliographic Details
Published in:	Medical science monitor Vol. 27; p. e934267
Main Authors:	Franchin, Giovanni, Mantri, Nikhitha, Zahid, Maleeha, Sun, Haozhe, Gongati, Sudharsan R, Ronderos, Diana M, Gadireddy, Snigdha, Chilimuri, Sridhar
Format:	Journal Article
Language:	English
Published:	United States International Scientific Literature, Inc 25-11-2021
Subjects:	Aged Antibodies, Monoclonal, Humanized - therapeutic use Arthritis, Rheumatoid - epidemiology Clinical Research Comorbidity COVID-19 - drug therapy COVID-19 - epidemiology Female Humans Immunotherapy - methods Middle Aged SARS-CoV-2 - immunology Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	BACKGROUND The use of monoclonal antibodies therapy (MAT) in early mild to moderate Coronavirus disease 2019 (COVID-19) has gained importance in recent times. However, there is limited information on the safety and efficacy of MAT in treating COVID-19 in patients with underlying rheumatologic diseases. Patients with rheumatologic diseases are usually on long-term corticosteroids and immunosuppressive therapy, which increases their risk for progressing to more severe forms of COVID-19. We report a case series of 4 patients with rheumatologic diseases who were treated with MAT for COVID-19. MATERIAL AND METHODS A retrospective observational study was conducted in our institution on patients with underlying rheumatological disorders who received MAT as per the EUA protocol of the FDA. RESULTS Two of the 4 patients were on immunosuppresive therapy at the time of receiving MAT. They recovered from COVID-19 without any adverse outcomes. No flare of underlying rheumatologic disease was noted. CONCLUSIONS MAT was observed to be a safe and effective therapy in 4 patients with rheumatological illnesses and COVID-19 treated at our hospital.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 Funds Collection Data Interpretation Literature Search Data Collection Study Design Manuscript Preparation Statistical Analysis
ISSN:	1643-3750 1234-1010 1643-3750
DOI:	10.12659/MSM.934267